AbbVie releases Phase 3 results from all-oral OBV/PTV/r treatment for GT1b chronic HCV infection

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan.



from The Medical News http://ift.tt/1yXomwO